Get the Stockscreener App
1.01
0.00%
0.00
Oncolytics Biotech Inc stock is traded at $1.01, with a volume of 498.57K.
It is up +0.00% in the last 24 hours and down -2.88% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.01
Open:
$1.02
24h Volume:
498.57K
Relative Volume:
0.59
Market Cap:
$108.68M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.8185
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
+1.70%
1M Performance:
-2.88%
6M Performance:
+36.49%
1Y Performance:
+13.82%
1-Day Range:
$0.98
$1.03
1-Week Range:
$0.9201
$1.06
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.01 | 108.68M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Why Oncolytics Biotech Inc. stock is recommended by analystsMarket Growth Report & Real-Time Buy Signal Notifications - ulpravda.ru
Will Oncolytics Biotech Inc. stock sustain high P E ratiosMarket Activity Summary & Consistent Return Strategy Ideas - DonanımHaber
Is Oncolytics Biotech Inc. stock trading near support levelsCPI Data & AI Enhanced Trading Signals - DonanımHaber
What analyst consensus says on Oncolytics Biotech Inc. stockJuly 2025 Retail & Reliable Entry Point Trade Alerts - ulpravda.ru
Quarterly Risk: Is Oncolytics Biotech Inc. stock a buy for dividend growthTrend Reversal & Fast Entry High Yield Stock Tips - ulpravda.ru
Published on: 2025-12-18 16:49:38 - ulpravda.ru
What hedge fund activity signals for Oncolytics Biotech Inc. stock2025 Stock Rankings & Safe Entry Point Identification - ulpravda.ru
[6-K] ONCOLYTICS BIOTECH INC Current Report (Foreign Issuer) | ONCY SEC FilingForm 6-K - Stock Titan
Oncolytics eyes controlled study for pelareorep in colorectal cancer - The Pharma Letter
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - BioSpace
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Cantech Letter
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Benzinga
Oncolytics Says Pelareorep Shows 33% Response Rate in Colorectal Cancer Patients; Shares Rise - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics rises on additional data for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer - Investing.com India
Oncolytics Biotech says data backs pelareorep in KRAS-mutant mCRC - marketscreener.com
Oncolytics Biotech Reports Promising Pelareorep Data in Colorectal Cancer - TipRanks
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer By Investing.com - Investing.com South Africa
United States Oncolytic Virus Therapy Market to Reach USD 199.98 - openPR.com
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Cantech Letter
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion - The Globe and Mail
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Oncolytics Biotech plans jurisdiction shift to Nevada - MSN
Oncolytics Biotech Plans Jurisdiction Shift to Nevada - The Globe and Mail
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech reschedules shareholder vote on U.S. domicile move By Investing.com - Investing.com Nigeria
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporat - pharmiweb.com
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada - The AI Journal
Oncolytics Biotech reschedules shareholder vote on U.S. domicile move - Investing.com
Oncolytics Biotech reschedules special meeting of shareholders to change jurisdiction of incorporation to Nevada - marketscreener.com
Oncolytics Biotech Reschedules Special Meeting Of Shareholders To Change Jurisdiction Of Incorporation To Nevada - TradingView — Track All Markets
Published on: 2025-12-08 13:44:04 - moha.gov.vn
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality - The Manila Times
Oncolytics to test immunotherapy against aggressive pancreatic cancer - Rare Cancer News
Is Oncolytics Biotech Inc. stock dividend yield sustainableMarket Volume Summary & Low Risk Profit Maximizing Plans - Newser
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - sharewise.com
Is Oncolytics Biotech Inc. stock undervalued vs historical averages2025 Historical Comparison & Weekly Watchlist for Hot Stocks - Newser
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality - The Globe and Mail
ONCY: Virtual Meeting Scheduled for December 8 - GuruFocus
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Oncolytics Biotech Inc. stock a buy for dividend growthJuly 2025 Trade Ideas & Safe Swing Trade Setups - moha.gov.vn
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire) - Aktiellt
Oncolytics Biotech Reports Q3 2025 Financial Results - MSN
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep - Aktiellt
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire) - Aktiellt
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):